Table 4.
Findings of the reviewed studies
Study Citation | Patient's characteristics | Severity of disease | Outcomes | Components | ||||
---|---|---|---|---|---|---|---|---|
Age | Comorbidities | Component | Form | Dose | Duration | |||
Farnoosh, et al25 | 50.7±14.4 | Hypertension 33.3% Diabetes 25% Rheumatic disease 4.2% Cardiovascular disease 12.5% Cancer |
Mild to moderate | Clinical improvement of symptoms and laboratory parameters | Melatonin | Oral | 3mg*3/day | 14 days |
Hasan ZT, et al 26 | 56.3±7.3 | Hypertension 53.2% Ischemic heart disease 15.8% Asthma 29.7% |
Severe | thrombosis, sepsis, and mortality rate | Melatonin | Oral | 10 mg | 14 days |
Marina Sánchez-Rico, et al 27 | 18–70 71–80 81+ |
diabetes mellitus diseases of the circulatory system diseases of the respiratory system neoplasms and diseases of the blood |
NA | in-hospital all-cause mortality | Melatonin | Oral | 2.61 mg | |
Ben Abdallah S et al 31 | 54.2 ± 17.3 | NA | Moderate | *For inpatients: death, need for ICU admission and length of ICU and hospital stay at 30-day *For outpatients: appearance of new symptoms, the need for hospitalization, need for ICU admission, and survival status |
Zinc | Oral | 25 mg | 15 days |
Oneel Patel, et al32 | 59.8 ± 16.8 | Hypertension Diabetes Chronic cardiovascular disease Chronic respiratory Disease Cirrhosis Hepatic Failure |
Moderate to severe | In non‐ventilated patients was assessed as the level of oxygenation expressed as oxygen flow (in liters/min) required to maintain blood oxygen levels (SpO2) above 94% and the worst (lowest) PaO2/FiO2 ratio in ventilated patients | Zinc | IV | 0.24 mg/kg/day | 7 days |
Margolin, et al33 | 45.2 (14.6) | Diabetes Hypertension Dyslipidemia Asthma |
Mild Outpatients |
the number of days required to reach a 50% reduction in symptoms | Vitamin C Zinc |
Oral | *8000 mg of ascorbic acid (to be divided over 2-3 times per day) *50 mg of zinc |
10 days |
Majidi, et al 35 | 59.42± 15 | Severe | Survival duration | Vitamin C | IV | 500 mg | 14 days | |
Poona Kumari, et al 36 | 52 ± 11 | Moderate to severe | *Days to be symptom-free * Days spent in the hospital * Need for mechanical ventilation |
Vitamin C | IV | |||
Castillo ME, et al38 | 53.14 +/- 10.77 | Lung disease Diabetes mellitus Hypertension Cardiovascular disease |
Moderate to Severe | Rate of ICU admission and deaths | Vitamin D | Oral | 0.532 mg 0.266 mg 0.266 mg |
Day1 Day3 Day7 |
Igor H Murai, et al39 | 56.2 [14.4] | Moderate to severe | length of stay in hospital | Vitamin D | Oral | 200 000 IU | 1 day |